Asset Details
Do you wish to reserve the book?
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Do you wish to request the book?
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
2017
Overview
In this trial involving patients with atherosclerotic disease who were receiving effective statin therapy, those who were assigned to receive anacetrapib, a CETP inhibitor, had a lower risk of major coronary events than did those in the placebo group.
Publisher
Massachusetts Medical Society
Subject
/ Anticholesteremic Agents - adverse effects
/ Anticholesteremic Agents - therapeutic use
/ Atherosclerosis - complications
/ Atherosclerosis - drug therapy
/ Cancer
/ Cholesterol Ester Transfer Proteins - antagonists & inhibitors
/ Cholesteryl ester transfer protein
/ Coronary Disease - epidemiology
/ Coronary Disease - mortality
/ Coronary Disease - prevention & control
/ Female
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Lipids
/ Male
/ Oxazolidinones - adverse effects
